Vivia Experts in NK-Engager ex vivo Assays
We preserve native environment containing complement proteins for NK Engagers ex vivo activity assays

  • Daratumumab ex vivo activity in >40 MM samples shows a high interpatient variability.
    • Daratumumab Ex Vivo Activity
    Figure 1. DR curves of Daratumumab ex vivo activity in >40 MM Samples.
  • Killing activity on MM plasma cells > NK & T Cells
  • Kinetically faster convergence Tumor cells vs NK & T Cells
    • Daratumumab Kinetics On Patient Cells
    Figure 2. Mean Fits Dose Response Curves (N=25-41)
  • Rituximab is more active against B Cells from RA than CLL
    • Rituximab Activity On B Cells
    Figure 3. Rituximab Normalized Dose Response Curves Against B Cells from RA or CLL
    • We preserve Native Environment:
    • Including RBCs and plasma, containing complement
    • Daratumumab dose response curves in >40 samples reveal:
    • High interpatient variability
    • Killing activity on plasma cells > NK & T cells
    • Activity correlates with CD38 Expression
    • Activity Doesn´t Correlate with NK/Tumor Cell Ratio
    • Rituximab in >50 CLL vs RA Samples:
    • Rituximab is more active against B Cells from RA than CLL
    Click Here